Page 261

movement disorders, 167, 168

nausea and vomiting, 7-8, 142, 145-154, 179, 245, 247

pain, 7-8, 141-145, 179

psychological effects, 5, 10, 109, 149

recommendations, 4, 5, 7-8, 9-10, 178, 179-180, 215, 245-255 (passim)

regulatory requirements, 195, 196, 200, 202, 208, 211, 213, 218, 256-257

single-patient trials, 139, 162

spasticity, 160-164, 165, 249

standards for, 7-8, 10, 138-139, 179-180

Cocaine, 3, 20, 70, 88, 90, 95, 102, 240

Colorado, vii, 1

Codeine, 143, 241

Cognitive effects, 49, 83-84, 89, 105, 106-107, 108, 124-125

disorientation, 4, 142, 203

memory, 35, 49, 53, 56, 84, 89, 106, 144, 173, 212

see also Psychological effects

Connecticut, 17

Controlled Substance Act, 16-17, 102, 198-204 (passim), 210, 213-219 (passim)

scheduling, 17, 102, 194, 198-213 (passim), 216-217, 218, 240-241, 256-257

Convulsions, see Seizures

Cost factors, 9, 16, 206-207, 243

antiemetics, 151, 152

drug development, 195, 196, 203, 206, 217-218

CP 47,497, 210

CP 55,244, 210

CP 55,940, 44, 46, 56, 201

Craving, 9, 90, 91-92

CT-3, 67, 209

Cytokines, 62, 66, 67, 112, 120, 157

D

DEA, see Drug Enforcement Administration

Delivery modes, see Drug delivery

Department of Health and Human Services, 199, 200, 201, 217

see also National Institutes of Health

Dependence, 6, 9, 57-59, 70, 84, 86, 237

animal research, 35

criteria, 87

legal issues, 16

marijuana as a gateway drug, 6-7, 9, 20-21, 98-101

predictors of, 93-98, 99, 100, 101, 126

see also Craving; Tolerance; Withdrawal symptoms

Depression, 22, 23, 29, 84, 95, 105, 155, 159

fluoxetine, 48

see also Dysphoria

Diagnostic and Statistical Manual of Mental Disorders, 84, 87

Diarrhea, 24, 155

District of Columbia, 17

Dizziness, 27, 121, 150, 158, 203

Dopamine, 58, 88, 92, 167, 168

Dosage factors, 137, 245, 248, 256

affinity, 42 (footnote)

AIDS wasting, 156, 157, 158

caffeine, 88

cardiovascular effects, 121

CBD, 36, 60-61

cognitive effects, 107

glaucoma treatment, 176, 177, 251

immune system effects, 60-63, 64-67, 68

morphine, 37

multiple sclerosis treatment, 163

neurological disorder treatment, 166, 169

overdosing, 37, 109, 206

pain treatment, 102, 142, 143, 149

psychological effects, 84, 85, 105

psychomotor effects, 51, 53, 85

reproductive effects, 122, 125

respiratory effects, 113

THC, 88, 89, 91, 122, 142, 176, 203, 206, 215, 255

anxiety, 36, 142, 149

glaucoma treatment, 176, 177, 251

pain treatment, 102, 142, 143, 149

psychoactive doses, 85

vomiting, 147, 154

vomiting, 147, 151, 152, 154

see also Dependence; Tolerance

Dronabinol, see Marinol

Drug Awareness Warning System, 102-103

Drug delivery, 7, 9, 151, 197, 199, 217, 239, 242, 245

inhalation, 7, 9, 57, 94, 150, 154, 165, 175, 197, 203, 206, 215 (footnote), 216, 242, 247, 251, 255; see Smoking, marijuana

injection, 39, 54, 57, 66, 67, 68, 85, 88, 94, 100, 122, 150, 151, 152, 159, 174, 175, 203



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement